- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06354556
Effect of Verapamil Tablets on the Pharmacokinetic of HRS-1893 Tablets in Healthy Subjects
May 6, 2024 updated by: Shandong Suncadia Medicine Co., Ltd.
Effect of Verapamil on the Pharmacokinetic of HRS-1893 Tablets in Healthy Subjects: a Single Center, Open, Single Arm, and Fixed Sequence Study
The purpose of this phase Ⅰ study is to evaluate the effect of oral verapamil tablets on the pharmacokinetics of HRS-1893 in healthy subjects.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
14
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Meng Fu
- Phone Number: +86 0518-82342973
- Email: meng.fu@hengrui.com
Study Contact Backup
- Name: Sheng Feng
- Phone Number: +86 0518-82342973
- Email: sheng.feng@hengrui.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100029
- Recruiting
- Beijing Anzhen Hospital
-
Contact:
- Yang Lin, Doctor
- Phone Number: 010-64456045
- Email: linyang@anzhengcp.com
-
Contact:
- Shan Jin, Doctor
- Phone Number: 010-64456045
- Email: jingshan@anzhengcp.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Understand the study procedures and methods, voluntarily participate in the study, comply with study requirements, and sign the written informed consent form (ICF).
- Male or female aged 18-55(adult healthy volunteers).
- Body mass index (BMI) between 19 and 28 kg/m2.
- Normal Electrocardiogram (ECG).
Exclusion Criteria:
- History of persistent tachyarrhythmia and syncope.
- A history of stomach or bowel surgery or excision.
- Positive results of hepatitis B surface antigen, hepatitis C antibody, syphilis antibody and human immunodeficiency virus antibody.
- Those who have participated in any clinical trials and have taken study drugs within 3 months before the first administration.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single arm
|
HRS-1893 tablet single dose
Verapamil tablet 80 mg tid
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum observed serum concentration (Cmax) for HRS-1893 after Single dose
Time Frame: from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose
|
from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose
|
Area under the plasma concentration versus time curve from time zero to last measurable timepoint (AUC0-t) for HRS-1893 after single dose
Time Frame: from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose
|
from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose
|
Area under the plasma concentration versus time curve from time zero extrapolated to infinity (AUC0-inf) for HRS-1893 after single dose
Time Frame: from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose
|
from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to maximum observed serum concentration (Tmax) for HRS-1893 after single dose
Time Frame: from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose
|
from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose
|
Elimination half-life (T1/2) for HRS-1893 after single dose
Time Frame: from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose
|
from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose
|
Apparent oral clearance (CL/F) for HRS-1893 after single dose
Time Frame: from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose
|
from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose
|
Apparent volume of distribution (Vz/F) for HRS-1893 after single dose
Time Frame: from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose
|
from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose
|
Accumulated amount of excretion (Ae) for HRS-1893 after single dose
Time Frame: from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose
|
from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose
|
Urinary excretion fraction(fe)for HRS-1893 after single dose
Time Frame: from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose
|
from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose
|
Renal clearance(CLr)for HRS-1893 after single dose
Time Frame: from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose
|
from Day 1 to Day 8 after the first dose and from Day 12 to Day 19 after the second dose
|
Number of subjects with adverse events and the severity of adverse events
Time Frame: from Day 1 to Day 24 after the first dose
|
from Day 1 to Day 24 after the first dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 26, 2024
Primary Completion (Estimated)
May 5, 2024
Study Completion (Estimated)
May 30, 2024
Study Registration Dates
First Submitted
April 3, 2024
First Submitted That Met QC Criteria
April 3, 2024
First Posted (Actual)
April 9, 2024
Study Record Updates
Last Update Posted (Actual)
May 7, 2024
Last Update Submitted That Met QC Criteria
May 6, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Aortic Valve Disease
- Heart Valve Diseases
- Aortic Stenosis, Subvalvular
- Aortic Valve Stenosis
- Cardiomyopathies
- Cardiomyopathy, Hypertrophic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Vasodilator Agents
- Membrane Transport Modulators
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Verapamil
Other Study ID Numbers
- HRS-1893-102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obstructive Hypertrophic Cardiomyopathy
-
French Cardiology SocietyCompleted1- Primary (Sarcomeric) Hypertrophic Cardiomyopathy | 2- Obstructive Hypertrophic Cardiomyopathy | 3- Non Obstructive Hypertrophic CardiomyopathyFrance
-
University of Sao PauloCompletedNon-obstructive Hypertrophic Cardiomyopathy | Obstructive Hypertrophic CardiomyopathyBrazil
-
Bristol-Myers SquibbActive, not recruitingHypertrophic Cardiomyopathy | Non-obstructive Hypertrophic Cardiomyopathy | Obstructive Hypertrophic CardiomyopathyDenmark, United States, Belgium, Czechia, France, Germany, Israel, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom
-
SuZhou Sinus Medical Technologies Co.,LtdNot yet recruiting
-
Bristol-Myers SquibbActive, not recruitingHOCM, Hypertrophic Obstructive CardiomyopathyUnited States
-
Shaare Zedek Medical CenterMedtronicUnknownHOCM, Hypertrophic Obstructive Cardiomyopathy
-
Hospital Clinic of BarcelonaUnknownHypertrophic Obstructive Cardiomyopathy (HOCM)Spain
-
Michele De BonisCompletedObstructive Hypertrophic Cardiomyopathy | Septal HypertrophyItaly
-
Montreal Heart InstituteCanadian Institutes of Health Research (CIHR)Enrolling by invitationCardiomyopathies | Hypertrophic Cardiomyopathy | Hypertrophic Obstructive Cardiomyopathy | Familial Hypertrophic CardiomyopathyCanada
-
Hangzhou Valgen Medtech Co., LtdNot yet recruitingObstructive Hypertrophic CardiomyopathyChina
Clinical Trials on HRS-1893 tablet
-
Shandong Suncadia Medicine Co., Ltd.RecruitingObstructive Hypertrophic CardiomyopathyChina
-
Shandong Suncadia Medicine Co., Ltd.Not yet recruitingAdvanced Malignant Tumour
-
Guangdong Hengrui Pharmaceutical Co., LtdEnrolling by invitationRefractory Chronic CoughChina
-
Guangdong Hengrui Pharmaceutical Co., LtdCompleted
-
Shandong Suncadia Medicine Co., Ltd.Not yet recruiting
-
Atridia Pty Ltd.CompletedInflammatory Bowel DiseaseAustralia
-
ModernaTX, Inc.Biomedical Advanced Research and Development AuthorityCompletedZika VirusUnited States, Puerto Rico
-
Shandong Suncadia Medicine Co., Ltd.Not yet recruiting
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
Grupo Español de Rehabilitación MultimodalUnknownArthroplasty, Replacement, Knee | Arthroplasty, Replacement, HipSpain